TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7

Genes and Immunity

Volumn 13, Issue 8, 2012, Pages 621-631

  Min, S ^a   Li, L ^a   Zhang, M ^a   Zhang, Y ^a   Liang, X ^a   Xie, Y ^a   He, Q ^a   Li, Y ^b   Sun, J ^b   Liu, Q ^a   Jiang, X ^a   Che, Y ^a   Yang, R ^a,c  

^a NANKAI UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

dendritic cells; MAP2K2; miR 27a; p38 MAPK; TAB3

Indexed keywords

CD4 ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; INTERLEUKIN 6; MICRORNA; MICRORNA 27A; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN MAP2K4; PROTEIN MAP2K7; PROTEIN TAB1; PROTEIN TAB2; PROTEIN TAB3; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; BASE SEQUENCE; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TH1 CELLS; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84870924300     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2012.45     Document Type: Article

References (50)

1. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10: 554-567.
2. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008; 29: 352-361.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
4. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
5. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM et al. Interleukin 17-producing CD4\+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
6. Tato CM, O'Shea JJ. Immunology: what does it mean to be just 17? Nature 2006; 441: 166-168.
7. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108: 1435-1440.
8. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291-295.
9. Zhou L, Chong MM, Littman DR. Plasticity of CD4\+ T cell lineage differentiation. Immunity 2009; 30: 646-655.
10. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3: 984-993.
11. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008; 226: 132-146.
12. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116: 935-944.
13. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
14. Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996; 272: 1179-1182.
15. Tsitsiou E, Lindsay MA. microRNAs and the immune response. Curr Opin Pharmacol 2009; 9: 514-520.
16. Davidson-Moncada J, Papavasiliou FN, Tam W. MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci 2010; 1183: 183-194.
17. Iwamoto S, Iwai S, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M et al. TNF-alpha drives human CD14\+ monocytes to differentiate into CD70\+ dendritic cells evoking Th1 and Th17 responses. J Immunol 2007; 179: 1449-1457.
18. Bonnefoy F, Couturier M, Clauzon A, Remy-Martin JP, Gaugler B, Tiberghien P et al. TGF-beta-exposed plasmacytoid dendritic cells participate in Th17 commitment. J Immunol 2011; 186: 6157-6164.
19. Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M. Interferonalpha-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS One 2011; 6: e17364.
20. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204: 1849-1861.
21. McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1. responses by Bordetella pertussis. J Exp Med 2002; 195: 221-231.
22. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
23. Chhabra R, Adlakha YK, Hariharan M, Scaria V, Saini N. Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and-independent apoptosis in human embryonic kidney cells. PLoS One 2009; 4: e5848.
24. Courties G, Seiffart V, Presumey J, Escriou V, Scherman D, Zwerina J et al. In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 2010; 116: 3505-3516.
25. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783-2810.
26. Arden KC. FoxO: linking new signaling pathways. Mol Cell 2004; 14: 416-418.
27. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009; 273: 233-242.
28. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007; 67: 11001-11011.
29. O'Garra A, Murphy KM. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 2009; 10: 929-932.
30. Cui G, Qin X, Zhang Y, Gong Z, Ge B, Zang YQ. Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J Biol Chem 2009; 284: 28420-28429.
31. Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet-and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol 2006; 177: 7579-7587.
32. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006; 6: 329-333.
33. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007; 19: 362-371.
34. Agrawal A, Dillon S, Denning TL, Pulendran B. ERK1-/-mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J Immunol 2006; 176: 5788-5796.
35. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
36. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol 2002; 168: 4711-4720.
37. Feng GJ, Goodridge HS, Harnett MM, Wei XQ, Nikolaev AV, Higson AP et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 1999; 163: 6403-6412.
38. Dillon S, Agrawal A, Van Dyke T, Landreth G, McCauley L, Koh A et al. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 2004; 172: 4733-4743.
39. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
40. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE et al. A CD4\+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-742.
41. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
42. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al. Regulatory CD4(\+)CD25(\+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-4772.
43. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20: 241-246.
44. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 2004; 16: 157-162.
45. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25\+ CD4\+ Tr cells. Blood 2005; 105: 1162-1169.
46. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235-2246.
47. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999; 163: 1037-1044.
48. Zhang Z, Liu Q, Che Y, Yuan X, Dai L, Zeng B et al. Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3. Cancer Res 2009; 70: 89-98.
49. Zeng B, Li H, Liu Y, Zhang Z, Zhang Y, Yang R. Tumor-induced suppressor of cytokine signaling 3 inhibits toll-like receptor 3 signaling in dendritic cells via binding to tyrosine kinase 2. Cancer Res 2008; 68: 5397-5404.
50. Zhang M, Liu Q, Mi S, Liang X, Zhang Z, Su X et al. Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol 2011; 186: 4716-4724.